pI: 4.9743 |
Length (AA): 253 |
MW (Da): 26573 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
1 | 252 | 1ef8 (A) | 1 | 256 | 21.00 | 0 | 1 | 1.23305 | 0.05 |
8 | 229 | 3ot6 (A) | 4 | 226 | 25.00 | 0 | 1 | 1.27577 | -0.94 |
8 | 253 | 3hrx (A) | 1 | 250 | 30.00 | 0 | 1 | 1.37033 | -0.26 |
9 | 232 | 4fn7 (A) | 5 | 228 | 29.00 | 0 | 1 | 1.32768 | -0.93 |
19 | 213 | 3l3s (A) | 18 | 215 | 34.00 | 0.000000000014 | 0.97 | 1.12935 | -0.22 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_130243)
Species | Accession | Gene Product |
---|---|---|
Drosophila melanogaster | Dmel_CG4594 | CG4594 gene product from transcript CG4594-RB |
Drosophila melanogaster | Dmel_CG4592 | CG4592 gene product from transcript CG4592-RB |
Drosophila melanogaster | Dmel_CG4598 | CG4598 gene product from transcript CG4598-RB |
Homo sapiens | ENSG00000167969 | enoyl-CoA delta isomerase 1 |
Leishmania braziliensis | LbrM.31.2600 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania braziliensis | LbrM.31.2520 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania braziliensis | LbrM.31.2470 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania donovani | LdBPK_312400.1 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania donovani | LdBPK_312320.1 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania infantum | LinJ.31.2400 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania infantum | LinJ.31.2320 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania major | LmjF.31.2250 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania major | LmjF.31.2330 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania mexicana | LmxM.30.2330 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Leishmania mexicana | LmxM.30.2250 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Mus musculus | ENSMUSG00000024132 | enoyl-Coenzyme A delta isomerase 1 |
Mycobacterium ulcerans | MUL_4319 | enoyl-CoA hydratase, EchA3 |
Trypanosoma brucei gambiense | Tbg972.8.7770 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma brucei gambiense | Tbg972.4.5080 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma brucei | Tb927.4.4910 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma brucei | Tb927.8.7530 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma congolense | TcIL3000_8_7780 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma congolense | TcIL3000_8_7920 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma cruzi | TcCLB.431357.10 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma cruzi | TcCLB.509261.30 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Trypanosoma cruzi | TcCLB.507107.40 | 3,2-trans-enoyl-CoA isomerase, mitochondrial precursor, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.4910 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.4910 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.4910 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.4.4910 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.8.7530 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.7530 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.7530 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.7530 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.